NCT06891417View on ClinicalTrials.gov

Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

1,560

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

January 3, 2028

Study Completion Date

January 3, 2028

Conditions
Chlamydia Trachomatis Immunization
Interventions
BIOLOGICAL

Chlamydia mRNA Vaccine

"Pharmaceutical Form: Suspension for injection~Route of Administration:~Intramuscular injection"

OTHER

Placebo

"Pharmaceutical Form:~Solution for injection~Route of Administration:~Intramuscular injection"

Trial Locations (6)

2010

Investigational Site Number : 0360005, Sydney

2035

Investigational Site Number : 0360006, Maroubra

2606

Investigational Site Number : 0360002, Bruce

4010

Investigational Site Number : 0360001, Albion

4222

Investigational Site Number : 0360003, Southport

4506

Investigational Site Number : 0360004, Morayfield

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT06891417 - Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years | Biotech Hunter | Biotech Hunter